DAX23.969 +2,4%Est505.837 +2,7%MSCI World4.343 -0,1%Top 10 Crypto9,2900 +1,8%Nas22.697 ±0,0%Bitcoin60.268 +0,1%Euro1,1623 +0,1%Öl89,58 -2,0%Gold5.202 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Lufthansa 823212 Rheinmetall 703000 NVIDIA 918422 TUI TUAG50 ExxonMobil 852549 Siemens Energy ENER6Y DroneShield A2DMAA Deutsche Telekom 555750 SAP 716460 RENK RENK73 Novo Nordisk A3EU6F Allianz 840400 Microsoft 870747 Amazon 906866 Shell (ex Royal Dutch Shell) A3C99G
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Ölpreise sinken: DAX beendet Handel weit im Plus -- US-Börsen kaum verändert -- Trump: Iran-Krieg "so gut wie beendet" -- VW, BioNTech, NIO, AT&T, Lumentum, Rheinmetall, Bitcoin & Co. im Fokus
Top News
KI-Chip-Rennen: So schätzt ein UBS-Top-Analyst die Aktien von NVIDIA, Micron und AMD ein KI-Chip-Rennen: So schätzt ein UBS-Top-Analyst die Aktien von NVIDIA, Micron und AMD ein
Warren Buffetts Wette auf die "Sogo Shosha": So schlagen sich die Japan-Investments von Berkshire Hathaway Warren Buffetts Wette auf die "Sogo Shosha": So schlagen sich die Japan-Investments von Berkshire Hathaway
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Aurinia Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
12,69 EUR +0,40 EUR +3,26 %
BMN
14,81 USD +0,45 USD +3,13 %
BTT
finanzen.net zero
Aurinia Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,64 Mrd. EUR

KGV7,70Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W7D4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA05156V1022

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAUPH

Aurinia Pharmaceuticals Aktien News

DatumMeistgelesen
BenzingaAurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
BenzingaEarnings Breakdown: Aurinia Pharmaceuticals Q4
ZacksAurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates
Wer­bungAurinia Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BenzingaEarnings Summary: Aurinia Pharmaceuticals Q4
BenzingaEarnings Preview: Aurinia Pharmaceuticals
ZacksIs Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?
ZacksAre Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
ZacksWhat Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now?
ZacksImplied Volatility Surging for Aurinia Pharmaceuticals Stock Options
ZacksIs Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
ZacksAurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates
ZacksAurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
ZacksImplied Volatility Surging for Aurinia Pharmaceuticals Stock Options
ZacksIs the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
ZacksAurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
ZacksZacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
BusinesswireAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
BusinesswireAurinia to Participate in Jefferies London Healthcare Conference
BusinesswireAurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
BusinesswireAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
BusinesswireAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
BusinesswireAurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
BusinesswireAurinia Announces Board Restructuring
BusinesswireAurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
BusinesswireAurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
BusinesswireAurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
BusinesswireAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
BusinesswireAurinia to Participate in Upcoming Investor Healthcare Conferences
BusinesswireAurinia Announces 2024 Annual General Meeting Results
BusinesswireAurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
BusinesswireAurinia Addresses Dubious Proposals Put Forth by Lucien Selce
BusinesswireAurinia Provides Update on Proxy Statement
BusinesswireAurinia Will Attend 2024 Jefferies Global Healthcare Conference
BusinesswireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
BusinesswireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
BusinesswireAurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
BusinesswireAurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
BusinesswireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
BusinesswireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
BusinesswireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals News: auf dieser Seite finden Sie alle Aurinia Pharmaceuticals News und Nachrichten zur Aurinia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Aurinia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Aurinia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.